Company profile
Syndesi Therapeutics company profile
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Business identity
- Contact email
- [email protected]
- Phone number
- +32 10 280 238
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0+
- Founded
- 2018-01-01, Year
Headquarters
- Headquarters
- Louvain-la-Neuve, Wallonia, Belgium
- Country code
- BE
- Continent
- Europe